论文部分内容阅读
胃肠道间质瘤(gastrointestinal stromal tumor,GIST)是胃肠道中最常见的间叶源性肿瘤,具有非定向分化的不同特征和生物学行为,其发病率为0.1/10万至0.2/10万[1]。手术是GIST最主要的治疗手段,因术后复发率及转移率高,故单靠手术治疗效果并不理想。新辅助治疗及靶向治疗成为GIST的研究热点,根据患者的临床表现、突变类型和个体差异,对其进行个体化治疗可以获得最佳的治疗效果。
Gastrointestinal stromal tumor (GIST), the most common mesenchymal tumor in the gastrointestinal tract, has different characteristics and biological behavior of non-directional differentiation with the incidence of 0.1 / 100,000 to 0.2 / 10 Wan [1]. Surgery is the most important treatment of GIST, because of postoperative recurrence rate and high transfer rate, so the effect of surgery alone is not satisfactory. Neo-adjuvant therapy and targeted therapy become hot spots in the study of GIST. According to their clinical manifestations, types of mutations and individual differences, individualized treatment can achieve the best therapeutic effect.